At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $179.59M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -2.89: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
179.59MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8510xvs all stocks
52-Week Change
-44.47%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
179.59MUSDvs all stocks (USD)
Enterprise Value
98.61MUSDvs all stocks (USD)
Forward P/E
-2.87xvs Biotechnology peers
Price to Book (MRQ)
2.48xvs Biotechnology peers
Enterprise to EBITDA
-0.8473xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-39.02%vs Biotechnology peers
Return on Equity (TTM)
-110.71%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Oct 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-98.56MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-73.86MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-45.10MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-83.25MUSDvs all stocks (USD)
Pre-tax Income
-45.58MUSDFY2025 · Dec 31, 2025Income Tax Expense
35.00KUSDFY2025 · Dec 31, 2025Net Income
-45.62MUSDFY2025 · Dec 31, 2025EBIT
-83.25MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-116.39MUSDFY2025 · Dec 31, 2025Research & Development
66.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
16.98MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.5200USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.5200USDFY2025 · Dec 31, 2025Basic Shares Outstanding
81.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
81.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-45.62MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-28.44MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
22.81MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-45.62MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
313.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
5.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.45MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
6.72MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-313.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-161.13MUSDFY2025 · Dec 31, 2025Sale of Investments
171.93MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
10.79MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
53.58MUSDFY2025 · Dec 31, 2025Shares Outstanding
80.89MSharesUpdated Oct 27, 2026Float Shares
74.60MSharesUpdated Oct 27, 2026Shares Short
7.85MSharesUpdated Oct 27, 2026Short Ratio
8.20daysvs all stocks
Short % of Shares Outstanding
9.66%vs all stocks
% Held by Insiders
0.33%vs all stocks
% Held by Institutions
58.76%vs all stocks
Total Cash (MRQ)
88.76MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.09USDUpdated Oct 27, 2026Total Debt (MRQ)
467.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0065xvs Biotechnology peers
Current Ratio (MRQ)
7.90xvs Biotechnology peers
Book Value per Share (MRQ)
0.8900USDUpdated Oct 27, 2026Total Assets
169.01MUSDvs all stocks (USD)
Total Current Assets
135.69MUSDFY2025 · Dec 31, 2025Total Liabilities
87.92MUSDFY2025 · Dec 31, 2025Total Non-current Assets
33.32MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
69.58MUSDFY2025 · Dec 31, 2025Total Current Liabilities
18.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
22.81MUSDFY2025 · Dec 31, 2025Other Short-term Investments
110.53MUSDFY2025 · Dec 31, 2025Accounts Payable
3.63MUSDFY2025 · Dec 31, 2025Short-term Debt
358.00KUSDFY2025 · Dec 31, 2025Long-term Debt
283.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
75.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-401.20MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
81.08MUSDvs all stocks (USD)
52-Week Low
1.35USDUpdated Oct 27, 202652-Week High
4.60USDUpdated Oct 27, 202652-Week Change
-44.47%vs all stocks
Beta
0.8510xvs all stocks
50-Day MA
2.78USDUpdated Oct 27, 2026200-Day MA
3.09USDUpdated Oct 27, 2026Avg 10-Day Volume
754.65KSharesUpdated Oct 27, 2026Avg 30-Day Volume
802.91KSharesUpdated Oct 27, 2026Diluted EPS (TTM)
-0.9000USDUpdated Oct 27, 2026Other Income / Expense
37.67MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 7.90Altman Z-Score: -2.89
Financial Health
Altman Z-Score -2.89: distress zoneCritical
Altman Z-Score: -2.89
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $179.59M, lower than 95% of all stocks globallySignificant
Market cap (USD): 179,587,145Global P5: 273,689,256.68
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 37,231,057.061
Companies that share the same coordination system — how they create, deliver, or capture value.
Alx Oncology Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Organogenesis Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
NervGen Pharma Corp.
Tier 1ProductionApproval-Gated PipelineRule
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Invivyd Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
MediWound Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Coherus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule